|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Alberta Cancer Board |
|---|---|
| Information provided by: | Alberta Cancer Board |
| ClinicalTrials.gov Identifier: | NCT00126815 |
Purpose
Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
| Condition |
|---|
|
Prostate Cancer |
| Study Type: | Observational |
| Study Design: | Natural History, Cross-Sectional, Defined Population, Retrospective Study |
| Official Title: | Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy |
Eligibility| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | NA-15-0002 |
| Study First Received: | August 3, 2005 |
| Last Updated: | September 11, 2006 |
| ClinicalTrials.gov Identifier: | NCT00126815 History of Changes |
| Health Authority: | Canada: Health Canada |
|
prostate cancer prostate specific antigen radiotherapy mathematical modeling |
|
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |